- Home
- ESAB vs LNTH Comparison
ESAB vs LNTH Comparison
Compare ESAB & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESAB | LNTH |
|---|---|---|
| Founded | 1904 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.6B |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ESAB | LNTH |
|---|---|---|
| Price | $67.90 | $99.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $138.56 | $87.00 |
| AVG Volume (30 Days) | ★ 846.5K | 835.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.27 | ★ 2.91 |
| Revenue | ★ $2,842,555,000.00 | $343,374,000.00 |
| Revenue This Year | $6.21 | N/A |
| Revenue Next Year | $5.33 | $14.19 |
| P/E Ratio | $56.60 | ★ $34.29 |
| Revenue Growth | ★ 3.71 | 3.62 |
| 52 Week Low | $64.86 | $49.67 |
| 52 Week High | $137.42 | $111.86 |
Technical Indicators
Market Signals| Indicator | ESAB | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 39.50 |
| Support Level | $64.86 | $98.81 |
| Resistance Level | $83.20 | $101.24 |
| Average True Range (ATR) | 2.69 | 0.43 |
| MACD | 0.60 | -0.03 |
| Stochastic Oscillator | 29.19 | 12.85 |
Price Performance
Historical ComparisonAbout ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.8 billion in revenue in 2025.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.